ALS Limited delivered a strong first half result with underlying earnings per share growing 21.6% to 42.3 cents, alongside a substantial 250 basis point expansion in underlying EBIT margin to 19.4%. The company generated underlying NPAT of $214.6 million, up 23.6% from the prior corresponding period, demonstrating robust operational leverage as revenue increased more modestly to $1.7 billion on a reported basis.
The standout performer was the Commodities division, which achieved organic revenue growth of 24.5% with underlying EBIT surging 36.4%. Within Commodities, Minerals delivered exceptional organic revenue growth of 30.4%, with EBIT margins improving 350 basis points to 34.7%. The division benefited from heightened global exploration activity and increased sample volumes, particularly from major and mid-tier miners deploying capital into exploration programs. This strength more than compensated for softer conditions in Life Sciences, where organic revenue growth languished at just 1.8%.
Life Sciences represents a material concern for investors. Reported revenue declined 6.6% to $978 million, with underlying EBIT down 12.6% to $134 million and margins contracting 95 basis points. While Food delivered respectable organic growth of 6.8% and Environmental grew 2.1%, Pharmaceutical experienced a 4.1% organic revenue decline. Management attributed underperformance to specific issues in the USA Environmental business and challenges at Nuvisan, flagging these as areas requiring operational improvements. The company now expects Life Sciences organic revenue growth of approximately 3% for the full year, below the mid-single digit guidance provided in May, with expectations for improvement to mid-single digit rates in the second half.
The company maintained a disciplined approach to capital allocation. Free cash flow reached $327.1 million, up 7.6%, reflecting strong cash conversion of 82%. Net debt stood at $1,182.3 million with leverage at a conservative 1.5 times, below the 1.7-2.3 times target range, providing capacity for growth initiatives. Hub laboratory upgrade projects progressed on schedule, with $34.1 million invested during the period and total cumulative spend reaching $127.8 million. Management expects approximately $35 million in additional hub lab spend during the second half.
The Board declared an interim dividend of 23.3 cents per share, partially franked at 35%, representing a 20% increase from the prior year interim and reflecting confidence in earnings momentum. The payout ratio of 55% aligns with historical practice.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARInvestors should monitor management’s ability to stabilize Life Sciences performance and validate the expectation for returning to mid-single digit organic growth in the second half. The trajectory of Commodities growth in the second half will also merit attention, given management anticipates moderation as comparisons strengthen. Currency headwinds remain a material risk, with every 1% movement in major currencies estimated to impact annualised underlying EBIT by approximately $3.5 million. This announcement is classified as price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About ALS Limited (ASX: ALQ)
ALS Limited is a global leader in laboratory testing, inspection, certification, and verification services, operating from approximately 350 sites across 65 countries. The company operates two main divisions: Commodities, which provides assaying and metallurgical services for the mining sector, and Life Sciences, which offers analytical testing for environmental, food, pharmaceutical, and consumer products markets. Headquartered in Brisbane, Australia, ALS serves major clients across Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR